Grappling with the androgen receptor: a new approach for treating advanced prostate cancer.
In this issue of Cancer Cell, Andersen et al. report on a small molecule that interacts with and blocks transactivation of the androgen receptor amino-terminal domain. This agent can overcome the shortcomings of clinically used antiandrogens, an important advance in the development of effective therapy for advanced prostate cancer.
Thompson
Timothy C
TC
Department of Genitourinary Medical Oncology, Research, Unit 18-3, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA. timthomp@mdanderson.org